Search Results

You are looking at 1 - 10 of 37 items for :

  • "lymph node metastases" x
Clear All
Open access

Mubashir Mulla and Klaus-Martin Schulte

radicality in differentiated thyroid carcinoma . World Journal of Surgery 1996 20 860 – 866 . (discussion 866) ( doi:10.1007/s002689900131 ). 9 Mulla M Schulte KM . Central cervical lymph node metastases in papillary thyroid cancer: a systematic

Open access

C Sui, Q He, R Du, D Zhang, F Li, G Dionigi, N Liang and H Sun

MA Pura J Goffredo P Dinan MA Reed SD Scheri RP Hyslop T Roman SA Sosa JA . Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer

Open access

Aleksandra Kukulska, Jolanta Krajewska, Zofia Kolosza, Ewa Paliczka-Cieslik, Aleksandra Kropinska, Agnieszka Pawlaczek, Zbigniew Puch, Kornelia Ficek, Teresa Lisik, Dorota Sygula, Zbigniew Wygoda, Jozef Roskosz, Jerzy Wydmanski and Barbara Jarzab

persons and 11 patients had extranodal extension. Ninety-one patients underwent radical surgical procedure (no micro- or macroscopic residual tumor, negative margins). Lymph node metastases were diagnosed in 96 patients treated with postoperative

Open access

Xu Han, Xuefeng Xu, Hongyun Ma, Yuan Ji, Dansong Wang, Tiantao Kuang, Wenchuan Wu, Bin Song, Gang Li, Gang Jin and Wenhui Lou

-67 index, elevated mitotic count, advanced AJCC TNM stage, vascular invasion and regional lymph-node metastases compared with WD-pNETs ( P  < 0.05). Interestingly, PD-pNECs were more likely to have elevated serum NSE levels and decreased serum CgA

Open access

Changjiao Yan, Meiling Huang, Xin Li, Ting Wang and Rui Ling

biomarker in driving aggressiveness in PTC continues debatable ( 7 , 8 ). The majority of researches claimed that BRAF V600E mutation was associated with poor clinicopathologic outcomes in patients with PTC, such as large tumor size, lymph node metastases

Open access

Chiara Mele, Maria Teresa Samà, Alessandro Angelo Bisoffi, Marina Caputo, Valentina Bullara, Stefania Mai, Gillian Elisabeth Walker, Flavia Prodam, Paolo Marzullo, Gianluca Aimaretti and Loredana Pagano

. Overall, 18/30 tumours were classified as stage I, followed by stage IV (5/30). Among patients who underwent lymph node dissection, seven patients had lymph node metastases. Lastly, tumour-associated thyroiditis was found in 7/30 cases. Bivariate

Open access

Barbora Pekova, Sarka Dvorakova, Vlasta Sykorova, Gabriela Vacinova, Eliska Vaclavikova, Jitka Moravcova, Rami Katra, Petr Vlcek, Pavla Sykorova, Daniela Kodetova, Josef Vcelak and Bela Bendlova

, histological variant, tumor stage, lymph node metastases and distant metastases are shown. C, classical variant; CF, classical and follicular variant; DM distant metastases; F, female; FV, follicular variant; LNM, lymph node metastases; M, male; O, other

Open access

Catarina Tavares, Maria João Coelho, Catarina Eloy, Miguel Melo, Adriana Gaspar da Rocha, Ana Pestana, Rui Batista, Luciana Bueno Ferreira, Elisabete Rios, Samia Selmi-Ruby, Bruno Cavadas, Luísa Pereira, Manuel Sobrinho Simões and Paula Soares

outliers. A total of 353 of the cases had information about tumor size, 362 had information for extrathyroidal extension, 282 had information for lymph node metastases (at the time of diagnosis) and all 374 had information about new tumor event (lymph node

Open access

Wei Sun, Boyuan Zheng, Zhihong Wang, Wenwu Dong, Yuan Qin and Hao Zhang

%, respectively ( 3 , 4 ). Patients with PTC develop cervical lymph node metastases in approximately 30–80% of cases ( 5 , 6 ). However, in patients with PTC, the significance of lymph node metastasis is a matter of debate. For example, some studies reported

Open access

Ana P Estrada-Flórez, Mabel E Bohórquez, Alejandro Vélez, Carlos S Duque, Jorge H Donado, Gilbert Mateus, Cesar Panqueba-Tarazona, Guadalupe Polanco-Echeverry, Ruta Sahasrabudhe, Magdalena Echeverry and Luis G Carvajal-Carmona

, capsular or vascular invasion, lymph node metastases, extra-thyroid extension, distant metastasis, stage (AJCC), vital status, and cause of death. Mutation status A pathologist (MEB) demarcated tumor regions with >80% tumor cells on hematoxylin and